Stay updated on IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial

Sign up to get notified when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The clinical trial record for IO102 with pembrolizumab, with or without chemotherapy, is displayed with its study design, participant criteria, locations, and outcome measures.
    Difference
    60%
    Check dated 2026-11-08T23:26:05.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page remains a 403 Forbidden error page, with its footer revision updated from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-01T23:35:32.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    A site-wide NIH notice about terminology changes appeared, and the site revision advanced from v3.7.1 to v3.7.2; the study page still shows a 403 error.
    Difference
    1%
    Check dated 2026-10-25T22:50:11.000Z thumbnail image
  4. Check
    34 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.0 to v3.7.1, while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-11T23:17:34.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error screen, replacing the study information with a standard access-denied layout. This makes the record temporarily inaccessible to users.
    Difference
    19%
    Check dated 2026-09-20T22:37:43.000Z thumbnail image
  6. Check
    76 days ago
    Change Detected
    Summary
    The NIH grant/contract note was added to the study identifiers, and the page revision tag was updated from v3.6.5 to v3.6.6.
    Difference
    0.1%
    Check dated 2026-08-30T22:23:15.000Z thumbnail image

Stay in the know with updates to IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IO102 Pembrolizumab in Metastatic NSCLC Clinical Trial page.